MR

FitXR's Immersive Zumba Studio is Live with a Trio of New Instructors

Retrieved on: 
Thursday, November 2, 2023

Today, FitXR , the leading VR workout platform with the largest offering of fitness classes, officially launched its highly anticipated Zumba Studio.

Key Points: 
  • Today, FitXR , the leading VR workout platform with the largest offering of fitness classes, officially launched its highly anticipated Zumba Studio.
  • Fusing the vibrant world of Zumba with the immersive capabilities of VR and MR, this new studio promises to bring a whole new dimension to dance fitness.
  • View the full release here: https://www.businesswire.com/news/home/20231102965634/en/
    Community is at the core of the FitXR experience, which is exemplified with the Zumba Studio.
  • With 32 classes planned for the year, FitXR's Zumba Studio will come in quarterly drops, starting with eight classes on November 2nd.

Tech Giants like Apple and Microsoft Lead the Way in the Booming Mixed Reality Market

Retrieved on: 
Wednesday, November 1, 2023

DUBLIN, Nov. 1, 2023 /PRNewswire/ -- The "Mixed Reality Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 1, 2023 /PRNewswire/ -- The "Mixed Reality Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global mixed reality market has experienced substantial growth, reaching a significant US$1,175.1 million in 2022.
  • Mixed reality (MR), also known as hybrid reality, combines elements of virtual reality (VR) and augmented reality (AR).
  • Key Trends in the Mixed Reality Market:
    The gaming and entertainment industry's increasing utilization of MR to provide users with immersive gaming experiences is a significant driver of market growth.

Micron Low-Power Memory Solution Boosts Mixed and Virtual Reality Experiences on Snapdragon XR2 Gen 2

Retrieved on: 
Thursday, October 19, 2023

Micron’s LPDDR5X and UFS 3.1 deliver next-level speed, performance and low-power consumption in the smallest form factors needed to support untethered mixed reality (MR) and virtual reality (VR) devices.

Key Points: 
  • Micron’s LPDDR5X and UFS 3.1 deliver next-level speed, performance and low-power consumption in the smallest form factors needed to support untethered mixed reality (MR) and virtual reality (VR) devices.
  • Micron’s LPDDR5X is the company’s most advanced low-power memory, delivering power efficiency enabled by its innovative 1-alpha process node technology and JEDEC power advancements .
  • The Snapdragon XR2 Gen 2 Platform offers a single-chip architecture to unlock next-level immersive MR and VR experiences in thinner and more comfortable headsets that don’t require an external battery pack.
  • Micron’s 1-alpha node process technology, which underpins Micron’s LPDDR5X, provides higher bit density, performance and energy efficiency for XR devices.

egnite, Inc. Unveils Research on Mitral Regurgitation at Transcatheter Cardiovascular Therapeutics Conference 2023

Retrieved on: 
Thursday, October 26, 2023

egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on mitral regurgitation (MR) was presented by cardiologist Rahul Sharma, MBBS, FRACP, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

Key Points: 
  • egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on mitral regurgitation (MR) was presented by cardiologist Rahul Sharma, MBBS, FRACP, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
  • These findings unveiled critical insights into treatment patterns and associated outcomes in patients with MR.
  • The implications of delayed treatment, particularly in moderate-to-severe MR, cannot be overstated, as it may lead to poor patient outcomes."
  • This research represents one of the largest real-world analyses of treatment patterns and associated outcomes for patients with MR and highlights the importance of timely intervention.

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Retrieved on: 
Tuesday, October 24, 2023

Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should.

Key Points: 
  • Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should.
  • As a result, MR and TR can lead to other cardiovascular issues as well as severely limit a person's quality of life.
  • "For more than two decades, Abbott has continued to evolve and expand its minimally invasive treatment options for mitral and tricuspid regurgitation.
  • TriClip is approved for use in more than 50 countries, including in Europe and Canada, and is an investigational device in the U.S.

New Physician Guidelines Recommend Contrast Enhanced Ultrasound to Diagnose Certain Liver Cancers

Retrieved on: 
Tuesday, October 3, 2023

New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.

Key Points: 
  • New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.
  • The new guidelines recommend CEUS for diagnosing HCC when MR and CT are inconclusive, unavailable or contraindicated.
  • CEUS uses FDA-approved “microbubble” ultrasound contrast agents (UCAs) that are administered intravenously during an ultrasound scan.
  • UCAs are manufactured and sold in the US and elsewhere by Bracco, Lantheus and GE Healthcare.

Affluent Medical : H1 2023 results. Major advances in clinical programs. Extension of cash horizon to February 2024.

Retrieved on: 
Thursday, September 28, 2023

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • This transcatheter approach avoids an invasive "open heart" procedure and associated complications to treat mitral valve insufficiency.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

EQS-News: Affluent Medical SA: H1 2023 RESULTS - Major advances in clinical programs - Extension of cash horizon to February 2024

Retrieved on: 
Thursday, September 28, 2023

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • In March 2023, Affluent Medical announced the successful first implantation of the Epygon biomimetic mitral heart valve in a patient with a severe mitral valve insufficiency profile combined with several comorbidity factors.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

Electronic Design Automation Market to grow by USD 7.50 billion from 2022 to 2027, Growth Driven by the growing significance of EDA in the electronic design process- Technavio

Retrieved on: 
Monday, September 18, 2023

The potential growth difference for the electronic design automation market from 2022 to 2027 is USD 7.50 billion, according to Technavio.

Key Points: 
  • The potential growth difference for the electronic design automation market from 2022 to 2027 is USD 7.50 billion, according to Technavio.
  • The growing significance of EDA in the electronic design process is a key factor driving market growth.
  • Get deeper insights into the market size, current market scenario, future growth opportunities, major growth driving factors, the latest trends, and much more.
  • Key Companies in the Electronic Design Automation Market:
    The Extended Reality Market size is estimated to grow at a CAGR of 43.09% between 2022 and 2027.

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities.

Retrieved on: 
Saturday, September 16, 2023

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities.

Key Points: 
  • Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities.
  • The results reported today consists of an interim data package of the first 20 patients treated at five centers across Europe at 1 year after implantation.
  • The clinical pilot study ‘Minerva’ evaluating the minimally invasive Epygon medical device to treat mitral valve regurgitation is currently being conducted in several clinical trial centers.
  • As the clinical study is progressing, Affluent Medical recently advanced 2 new valve sizes (40 & 42 size).